{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T10:51:52Z","timestamp":1781952712229,"version":"3.54.5"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ijgc.2025.102832","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T09:29:46Z","timestamp":1772443786000},"page":"102832","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Role of adjuvant therapy de-escalation for low-grade endometrioid endometrial cancer with adnexal only metastasis: call for research"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1655-6877","authenticated-orcid":false,"given":"Hadi","family":"Erfani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmeline L.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew W.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6232-8701","authenticated-orcid":false,"given":"Koji","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6960-4414","authenticated-orcid":false,"given":"Lynda D.","family":"Roman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason D.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijgc.2025.102832_bib1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102832_bib2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102832_bib3","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/AOG.0000000000004676","article-title":"The changing landscape of gynecologic cancer mortality in the United States","volume":"139","author":"Giaquinto","year":"2022","journal-title":"Obstet Gynecol"},{"issue":"24","key":"10.1016\/j.ijgc.2025.102832_bib4","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1002\/cncr.34479","article-title":"Annual report to the nation on the status of cancer, part 1: National cancer statistics","volume":"128","author":"Cronin","year":"2022","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102832_bib5","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.ijgc.2025.102832_bib6","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1200\/JCO.19.02888","article-title":"De-escalation of locoregional therapy in low-risk disease for DCIS and early-stage invasive cancer","volume":"38","author":"Hwang","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ijgc.2025.102832_bib7","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S1470-2045(25)00379-1","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial","volume":"26","author":"Post","year":"2025","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102832_bib8","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/path.5373","article-title":"Clinicopathological and molecular characterisation of \u2018multiple-classifier\u2018 endometrial carcinomas","volume":"250","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J Pathol"},{"issue":"9213","key":"10.1016\/j.ijgc.2025.102832_bib9","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/S0140-6736(00)02139-5","article-title":"Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma","volume":"355","author":"Creutzberg","year":"2000","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102832_bib10","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.ygyno.2003.11.048","article-title":"A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study","volume":"92","author":"Keys","year":"2004","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102832_bib11","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ijgo.14923","article-title":"FIGO staging of endometrial cancer: 2023","volume":"162","author":"Berek","year":"2023","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.ijgc.2025.102832_bib12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ygyno.2024.04.016","article-title":"Prognostic performance of the 2023 FIGO staging schema for endometrial cancer","volume":"187","author":"Matsuo","year":"2024","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2025.102832_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113533","article-title":"Low-grade endometrioid endometrial cancer with adnexal only metastasis: evaluation of de-escalation of adjuvant therapy","volume":"200","author":"Matsuo","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijgc.2025.102832_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113316","article-title":"Validation of the 2023 FIGO staging schema for advanced endometrial cancer","volume":"193","author":"Matsuo","year":"2023","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.ijgc.2025.102832_bib15","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv442","article-title":"Making a difference: distinguishing two primaries from metastasis in synchronous tumors of the ovary and uterus","volume":"108","author":"Dizon","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.ijgc.2025.102832_bib16","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv427","article-title":"Massively parallel sequencing-based clonality analysis of synchronous endometrioid endometrial and ovarian carcinomas","volume":"108","author":"Schultheis","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.ijgc.2025.102832_bib17","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv428","article-title":"Synchronous endometrial and ovarian carcinomas: evidence of clonality","volume":"108","author":"Anglesio","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102832_bib18","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/IGC.0000000000000019","article-title":"Synchronous ovarian and endometrial cancer--an international multicenter case-control study","volume":"24","author":"Heitz","year":"2014","journal-title":"Int J Gynecol Cancer"},{"issue":"7403","key":"10.1016\/j.ijgc.2025.102832_bib19","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature10983","article-title":"The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups","volume":"486","author":"Curtis","year":"2012","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102832_bib20","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ygyno.2018.10.033","article-title":"Risk-based stratification of carcinomas concurrently involving the endometrium and ovary","volume":"152","author":"Turashvili","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102832_bib21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/his.13977","article-title":"Revising the WHO classification: female genital tract tumours","volume":"76","author":"Cree","year":"2020","journal-title":"Histopathology"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102832_bib22","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00428-020-03007-z","article-title":"ESGO\/ESTRO\/ESP Guidelines for the management of patients with endometrial carcinoma","volume":"478","author":"Concin","year":"2021","journal-title":"Virchows Arch"},{"issue":"8","key":"10.1016\/j.ijgc.2025.102832_bib23","doi-asserted-by":"crossref","first-page":"284","DOI":"10.6004\/jnccn.2025.0038","article-title":"NCCN Guidelines\u00ae insights: uterine neoplasms, version 3.2025","volume":"23","author":"Abu-Rustum","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102832_bib24","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.pas.0000180854.28831.77","article-title":"The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome","volume":"30","author":"Medeiros","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ijgc.2025.102832_bib25","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ygyno.2023.10.004","article-title":"Intraluminal tumor cells and prognostic accuracy of endometrial cancer stage criteria: a multi-institution study","volume":"178","author":"Felix","year":"2023","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102832_bib26","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1097\/PGP.0000000000000524","article-title":"Pathologic prognostic factors in endometrial carcinoma (other than tumor type and grade)","volume":"38","author":"Singh","year":"2019","journal-title":"Int J Gynecol Pathol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102832_bib27","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ygyno.2017.09.027","article-title":"Prognosis of women with stage I endometrioid endometrial cancer and synchronous stage I endometrioid ovarian cancer","volume":"147","author":"Matsuo","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"47","key":"10.1016\/j.ijgc.2025.102832_bib28","doi-asserted-by":"crossref","first-page":"28757","DOI":"10.18632\/oncotarget.25550","article-title":"Trends and outcomes of women with synchronous endometrial and ovarian cancer","volume":"9","author":"Matsuo","year":"2018","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102832_bib29","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ygyno.2004.05.006","article-title":"Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases","volume":"94","author":"Soliman","year":"2004","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102832_bib30","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s00404-019-05288-5","article-title":"The prognosis of stage IA synchronous endometrial endometrioid and ovarian carcinomas","volume":"300","author":"Zhan","year":"2019","journal-title":"Arch Gynecol Obstet"},{"issue":"10","key":"10.1016\/j.ijgc.2025.102832_bib31","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ijgc-2024-005567","article-title":"2009 International Federation of Gynecology and Obstetrics (FIGO) stage IIIA endometrial cancer: oncologic outcomes based on involvement of adnexa, serosa, or both","volume":"34","author":"Rios-Doria","year":"2024","journal-title":"Int J Gynecol Cancer"},{"issue":"9717","key":"10.1016\/j.ijgc.2025.102832_bib32","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0140-6736(09)62163-2","article-title":"Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial","volume":"375","author":"Nout","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102832_bib33","doi-asserted-by":"crossref","first-page":"e187","DOI":"10.1016\/j.ijrobp.2012.03.030","article-title":"Sexual functioning among endometrial cancer patients treated with adjuvant high-dose-rate intra-vaginal radiation therapy","volume":"84","author":"Damast","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102832_bib34","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/IGC.0b013e3182481611","article-title":"Sexual function after intracavitary vaginal brachytherapy for early-stage endometrial carcinoma","volume":"22","author":"Quick","year":"2012","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102832_bib35","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ygyno.2010.10.017","article-title":"Late GI and bladder toxicities after radiation for uterine cancer","volume":"120","author":"Samper-Ternent","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102832_bib36","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ygyno.2017.11.007","article-title":"Life after endometrial cancer: a systematic review of patient-reported outcomes","volume":"148","author":"Shisler","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"11","key":"10.1016\/j.ijgc.2025.102832_bib37","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.ejca.2011.11.014","article-title":"Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative radiation therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data","volume":"48","author":"Nout","year":"2012","journal-title":"Eur J Cancer"},{"issue":"21","key":"10.1016\/j.ijgc.2025.102832_bib38","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1200\/JCO.2008.20.2424","article-title":"Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial","volume":"27","author":"Nout","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102832_bib39","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.ygyno.2007.04.015","article-title":"Cost-effectiveness of adjuvant radiotherapy in intermediate risk endometrial cancer","volume":"106","author":"Rankins","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102832_bib40","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.brachy.2017.11.012","article-title":"Cost-effectiveness of adjuvant intravaginal brachytherapy in high-intermediate risk endometrial carcinoma","volume":"17","author":"Stahl","year":"2018","journal-title":"Brachytherapy"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102832_bib41","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ygyno.2021.10.071","article-title":"Cost-effectiveness analysis of tumor molecular classification in high-risk early-stage endometrial cancer","volume":"164","author":"Orellana","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102832_bib42","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1136\/ijgc-2022-004039","article-title":"Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program","volume":"33","year":"2023","journal-title":"Int J Gynecol Cancer"},{"issue":"29","key":"10.1016\/j.ijgc.2025.102832_bib43","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy","volume":"38","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijgc.2025.102832_bib44","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ygyno.2025.01.006","article-title":"Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: ancillary analysis of GOG-0258","volume":"193","author":"Clements","year":"2025","journal-title":"Gynecol Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25019565?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25019565?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T17:22:32Z","timestamp":1774459352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25019565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1048891X25019565"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102832","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of adjuvant therapy de-escalation for low-grade endometrioid endometrial cancer with adnexal only metastasis: call for research","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102832","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102832"}}